Neuromeka뉴로메카

Neuromeka remains deeply loss-making on a trailing basis, with revenue shrinking and a share price far below its 52-week high.

Neuromeka, a Korean maker of collaborative robots and robot components, reported trailing twelve-month revenue of about ₩18.2B to H1 2026 against an operating loss of about ₩16.3B and a net loss of about ₩40.2B. Revenue fell 25% in 2025 after a strong 2024, and the company carries about ₩48.0B in borrowings against about ₩10.2B in cash. The share price closed at ₩16,890 on 2026-10-27, down 15.8% over one month and 4.2% over one year.

What stands out

• Trailing operating margin is about -89.5% and net margin about -221.2%, with losses persisting in every annual period shown from 2022 to 2025.
• Free cash flow is negative at about -₩23.8B on a trailing basis, and liabilities are 148.1% of equity.
• Price-to-book is about 10.9x and price-to-sales about 21.8x; P/E cannot be computed because earnings are negative.
• The filings list a major sales or supply contract dated 2026-10-01, but the data does not give its value or terms.
• Foreign ownership fell from 6.6% to 3% over about 60 days, while retail investors were net buyers over the last 20 days.
• Recent headlines centre on CEO Park Jong-hoon's ₩5B donation to POSTECH and on the company's robotics profile, not on financial results.

What to watch

• The next half-year or annual results, and whether revenue stabilises after the 2025 decline and losses narrow.
• Whether the cash position of about ₩10.2B can cover borrowings of about ₩48.0B and negative free cash flow without new financing; the data does not show any financing plans.
• Further 5%+ holding reports and insider shareholding filings, which the recent filing list shows have been frequent.